EUVIMEDObjevte EUVIMED
Open access · CC BY-NC-ND 4.0

Single‐Step Universal First‐Trimester Cytomegalovirus Screening and Valacyclovir Prophylaxis in Pregnancy: A Cost‐Utility Analysis in a High Seroprevalence Setting

Zhi Zhen Lim iD, Clarence Ong, Ching Yee Chan, Kee Thai Yeo, Wei Yee Wan, Jerry Kok Yen Chan, Wei Ching Tan, Lay Kok Tan, Pamela Palasanthiran, Yi Wang, Liying Yang iD

Prenatal Diagnosis · 2025

DOI: 10.1002/pd.6848 ↗

At a glance

Journal article in Prenatal Diagnosis, 2025. Written by Zhi Zhen Lim and 10 co-authors. Institution: Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore. Major MEDLINE topics: Cytomegalovirus, Cytomegalovirus Infections, Valacyclovir, Antiviral Agents. Cited 6 times so far (Crossref); 50 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: National Medical Research Council SingHealth PULSES Seed Grant.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Objective

To evaluate the cost‐effectiveness of first trimester single‐step universal cytomegalovirus (CMV) serological screening with valacyclovir as vertical transmission prophylaxis versus routine ultrasound‐directed testing.

Methods

A payer perspective cost‐utility analysis was conducted on a hypothetical population of 100,000 pregnant women for a time horizon of 9 month of full‐term pregnancy and the lifetime of children. Using a decision‐tree and Markov model, we assessed quality‐adjusted life years (QALYs) gained by preventing congenital CMV (cCMV) sequelae against the costs of universal screening and valacyclovir prophylaxis.

Results

The ICER for universal screening strategy was USD125,864 (SGD170,087)/QALY‐gained compared to routine ultrasound‐directed testing. It prevented approximately 54 cCMV infections, 18 cases of symptomatic infections, and 17 cases of sensorineural hearing loss (SNHL) and cognitive impairment by age of 5 per 100,000 mothers screened. The primary factors influencing cost‐effectiveness include the effectiveness of VCV in preventing vertical CMV transmission, the prevalence of primary CMV infection during pregnancy, the probability of symptomatic congenital CMV following periconceptional infection, and the cost of serological testing.

Conclusions

Although the ICER of universal CMV screening appears high in absolute terms, it compares favorably with ICER of commonly offered antenatal screening methods such as first trimester non‐invasive prenatal testing for women at intermediate risk of Trisomy 21. Universal screening has the potential for averting childhood morbidity at birth and by 5‐years‐old. Important variables influencing the ICER include the effectiveness of valacyclovir in preventing vertical transmission, prevalence of primary CMV infection, probability of symptomatic cCMV after periconception primary infection and cost of serology tests.

Subjects

MeSH terms (MEDLINE)

CytomegalovirusCytomegalovirus InfectionsValacyclovirAntiviral AgentsPregnancy Trimester, FirstSeroepidemiologic StudiesHumansFemalePregnancyCost-Benefit AnalysisQuality-Adjusted Life YearsPregnancy Complications, InfectiousInfectious Disease Transmission, Vertical

Author keywords

congenital cytomegalovirus infectioncost‐effectivenesscytomegalovirus infectionfetal infectionsmaternal serology screeningperinatal infection

Substances

ValacyclovirAntiviral Agents

Authors and institutions

  • Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore.
  • Department of Otolaryngology, KK Women's and Children's Hospital, Singapore.
  • Department of Neonatology, KK Women's and Children's Hospital, Singapore.
  • Department of Microbiology, Singapore General Hospital, Singapore.
  • Department of Reproductive Medicine, KK Women's and Children's Hospital, Singapore.
  • Department of Maternal-Fetal Medicine, KK Women's and Children's Hospital, Singapore.

ORCID profiles: Zhi Zhen Lim, Liying Yang

Funding

  • National Medical Research Council SingHealth PULSES Seed Grant

Cite

APA

Lim, Z. Z., Ong, C., Chan, C. Y., Yeo, K. T., Wan, W. Y., Chan, J. K. Y., Tan, W. C., Tan, L. K., Palasanthiran, P., Wang, Y., & Yang, L. (2025). Single‐Step Universal First‐Trimester Cytomegalovirus Screening and Valacyclovir Prophylaxis in Pregnancy: A Cost‐Utility Analysis in a High Seroprevalence Setting. Prenatal Diagnosis. https://doi.org/10.1002/pd.6848

Vancouver

Lim ZZ, Ong C, Chan CY, Yeo KT, Wan WY, Chan JKY, et al. Single‐Step Universal First‐Trimester Cytomegalovirus Screening and Valacyclovir Prophylaxis in Pregnancy: A Cost‐Utility Analysis in a High Seroprevalence Setting. Prenatal Diagnosis. 2025. doi:10.1002/pd.6848

BibTeX
@article{Lim2025,
  author = {Lim, Zhi Zhen and Ong, Clarence and Chan, Ching Yee and Yeo, Kee Thai and Wan, Wei Yee and Chan, Jerry Kok Yen and Tan, Wei Ching and Tan, Lay Kok and Palasanthiran, Pamela and Wang, Yi and Yang, Liying},
  title = {Single‐Step Universal First‐Trimester Cytomegalovirus Screening and Valacyclovir Prophylaxis in Pregnancy: A Cost‐Utility Analysis in a High Seroprevalence Setting},
  journal = {Prenatal Diagnosis},
  year = {2025},
  doi = {10.1002/pd.6848}
}
Start for free →